394 related articles for article (PubMed ID: 26235542)
1. A new potent analgesic agent with reduced liability to produce morphine tolerance.
Kiraly K; Caputi FF; Hanuska A; Kató E; Balogh M; Köles L; Palmisano M; Riba P; Hosztafi S; Romualdi P; Candeletti S; Ferdinandy P; Fürst S; Al-Khrasani M
Brain Res Bull; 2015 Aug; 117():32-8. PubMed ID: 26235542
[TBL] [Abstract][Full Text] [Related]
2. Peripheral antinociceptive efficacy and potency of a novel opioid compound 14-O-MeM6SU in comparison to known peptide and non-peptide opioid agonists in a rat model of inflammatory pain.
Khalefa BI; Mousa SA; Shaqura M; Lackó E; Hosztafi S; Riba P; Schäfer M; Ferdinandy P; Fürst S; Al-Khrasani M
Eur J Pharmacol; 2013 Aug; 713(1-3):54-7. PubMed ID: 23665110
[TBL] [Abstract][Full Text] [Related]
3. A novel µ-opioid receptor ligand with high in vitro and in vivo agonist efficacy.
Lacko E; Varadi A; Rapavi R; Zador F; Riba P; Benyhe S; Borsodi A; Hosztafi S; Timar J; Noszal B; Furst S; Al-Khrasani M
Curr Med Chem; 2012; 19(27):4699-707. PubMed ID: 22934777
[TBL] [Abstract][Full Text] [Related]
4. Morphine and fentanyl differently affect MOP and NOP gene expression in human neuroblastoma SH-SY5Y cells.
Caputi FF; Lattanzio F; Carretta D; Mercatelli D; Candeletti S; Romualdi P
J Mol Neurosci; 2013 Oct; 51(2):532-8. PubMed ID: 23715695
[TBL] [Abstract][Full Text] [Related]
5. The Peripheral Versus Central Antinociception of a Novel Opioid Agonist: Acute Inflammatory Pain in Rats.
Balogh M; Zádori ZS; Lázár B; Karádi D; László S; Mousa SA; Hosztafi S; Zádor F; Riba P; Schäfer M; Fürst S; Al-Khrasani M
Neurochem Res; 2018 Jun; 43(6):1250-1257. PubMed ID: 29725918
[TBL] [Abstract][Full Text] [Related]
6. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
7. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
8. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
10. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
11. Increased glutamate synaptic transmission in the nucleus raphe magnus neurons from morphine-tolerant rats.
Bie B; Pan ZZ
Mol Pain; 2005 Feb; 1():7. PubMed ID: 15813995
[TBL] [Abstract][Full Text] [Related]
12. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
13. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
14. Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence.
Lutfy K; Parikh D; Lee DL; Liu Y; Ferrini MG; Hamid A; Friedman TC
Neuroscience; 2016 Aug; 329():318-25. PubMed ID: 27208618
[TBL] [Abstract][Full Text] [Related]
15. Efficacy-Based Perspective to Overcome Reduced Opioid Analgesia of Advanced Painful Diabetic Neuropathy in Rats.
Balogh M; Zádor F; Zádori ZS; Shaqura M; Király K; Mohammadzadeh A; Varga B; Lázár B; Mousa SA; Hosztafi S; Riba P; Benyhe S; Gyires K; Schäfer M; Fürst S; Al-Khrasani M
Front Pharmacol; 2019; 10():347. PubMed ID: 31024314
[TBL] [Abstract][Full Text] [Related]
16. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
[TBL] [Abstract][Full Text] [Related]
17. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
18. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
Cichewicz DL; Martin ZL; Smith FL; Welch SP
J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
[TBL] [Abstract][Full Text] [Related]
19. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
[TBL] [Abstract][Full Text] [Related]
20. New Morphine Analogs Produce Peripheral Antinociception within a Certain Dose Range of Their Systemic Administration.
Lackó E; Riba P; Giricz Z; Váradi A; Cornic L; Balogh M; Király K; Csekő K; Mousa SA; Hosztafi S; Schäfer M; Zádori ZS; Helyes Z; Ferdinandy P; Fürst S; Al-Khrasani M
J Pharmacol Exp Ther; 2016 Oct; 359(1):171-81. PubMed ID: 27435180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
